Egetis Therapeutics AB (publ) (EGTX.ST) Research

Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.

Market snapshot

Symbol
EGTX.ST
Price
$5.26
Day change
-1.13%
Market cap
$2.0B
P/E ratio
-5.31x
52-week range
3.625-7.07
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • BioInvent International AB (publ) (BINV.ST)
  • Diamyd Medical AB (publ) (DMYD-B.ST)
  • Devyser Diagnostics AB (publ) (DVYSR.ST)
  • Hansa Biopharma AB (publ) (HNSA.ST)
  • Humana AB (publ) (HUM.ST)
  • Oncopeptides AB (publ) (ONCO.ST)
  • Saniona AB (publ) (SANION.ST)
  • SynAct Pharma AB (SYNACT.ST)

Open Egetis Therapeutics AB (publ) (EGTX.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.